Ampio Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Ampio Pharmaceuticals generated cash of -$8,564,000, which is more than the previous year. Cash used in financing activities reached the amount of $0 last year. Net change in cash is therefore -$8,564,000.
Cash Flow
| 2014 | -30.74M | -8.65M | 63.40M |
|---|---|---|---|
| 2015 | -26.44M | -1.77M | 4.85M |
| 2016 | -14.62M | -6.84K | 3.52M |
| 2017 | -11.40M | -72.32K | 14.79M |
| 2018 | -12.13M | -564.27K | 12.07K |
| 2019 | -15.38M | -22K | 14.35K |
| 2020 | -14.72M | -63K | 25.60M |
| 2021 | -14.08M | -97K | 30.73M |
| 2022 | -21.12M | 0 | -111 |
| 2023 | -8.56M | 0 | 0 |
AMPE Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 12.65M | 33.89M | 17.34M | 6.53M | 7.58M | 8.20M | 4.89M | 15.99M | 50.32M | 26.30M |
Operating activities | ||||||||||
Net income | -8.63M | -16.33M | -17.07M | -15.89M | -13.63M | 33.98M | -51.89M | -19.16M | -33.71M | -39.04M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 122K | 1.04M | 1.09M | 1.17M | 1.27M | 1.28M | 1.21M | 1.21M | 1.13M | 439.09K |
Stock-based compensation expense | 159K | 953K | 2.72M | 1.27M | 405K | 443.78K | 744.87K | 1.51M | 6.17M | 7.85M |
| Deferred income tax benefit | 159K | 953K | 2.72M | 1.27M | 405K | 443.78K | 744.87K | 1.51M | 6.17M | 7.85M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 38.45K | -38 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 42.23K | 0 | 0 |
Accounts payable | 0 | -3.95M | 3.26T | -2.47T | 2.7M | -1.46M | 2.07M | -1.09M | -426.07K | 1.02M |
Cash generated by operating activities | -8.56M | -21.12M | -14.08M | -14.72M | -15.38M | -12.13M | -11.40M | -14.62M | -26.44M | -30.74M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -16.3M | 0 |
Investments In Property Plant And Equipment | 0 | 0 | -97K | -63K | -22K | -564.27K | -72.32K | -6.84K | -235.65K | -8.66M |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.54M | 0 |
Cash generated by investing activities | 0 | 0 | -97K | -63K | -22K | -564.27K | -72.32K | -6.84K | -1.77M | -8.65M |
Financing activities | ||||||||||
Common Stock Issued | 98K | -32K | 33.01M | 26.19M | 12.14M | 0 | 13.33M | 3.90M | 30K | 68.40M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | -79 | -186K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.17M | 0 |
Cash used in financing activities | 0 | -111 | 30.73M | 25.60M | 14.35K | 12.07K | 14.79M | 3.52M | 4.85M | 63.40M |
Net Change In Cash | -8.56M | -21.23M | 16.54M | 10.81M | -1.05M | -623.67K | 3.31M | -11.10M | -23.36M | 24.01M |
Cash at end of period | 4.08M | 12.65M | 33.89M | 17.34M | 6.53M | 7.58M | 8.20M | 4.89M | 26.95M | 50.32M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |